INSIGHTS

When early research findings challenged the original plan, Spinnaker adapted quickly—broadening the scope to uncover real-world insights that reshaped the strategy. This post explores how flexible thinking and early listening led to a stronger, more impactful outcome for the client.

Psychiatry is emerging as the most capital-efficient segment in CNS, attracting major biopharma investment with late-phase assets, validated endpoints, and scalable commercial models. As neurodegeneration remains high-risk, psychiatry offers near-term ROI and strategic fit across the value chain.

Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.

The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.

To thrive in today’s evolving healthcare market landscape, medical device companies must take a cohesive, strategic approach to address the complexities and opportunities of the current environment. Success will hinge on aligning commercial models with customer priorities, reducing inefficiencies, and leveraging technology to drive smarter decisions. By Jeremy Cohen, Spinnaker Life Sciences Strategy Consulting.